Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
about
Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current ManagementAPF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroThe development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomitingSEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016).Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy.Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis.Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populationsEffectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta-analysis of 143 randomized controlled trials.Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice.Olanzapin hilft gegen Zytostatika-Erbrechen.The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study.Getting it right the first time: recent progress in optimizing antiemetic usage.Diabetes and the Stomach.Prevention of chemotherapy-induced vomiting in children receiving multiple-day cisplatin chemotherapy: A hospital-based, retrospective cohort study.A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment.Management of Patients With Chemotherapy-Induced Nausea and Vomiting.Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-concluding thoughts.Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter studyEvolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomitingSymptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung CancerOlanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
P2860
Q30235971-F584057B-F4B8-4DE5-9D2F-909E6B5B9EBAQ33734386-D97BB15C-4125-4431-BA01-9CE69F9D3DC7Q33749052-BD7EC77C-31AA-40FA-9305-D0B9D24A1B88Q37475199-1378405D-F922-41C3-A77D-BA0914BC5D58Q37480802-8970F802-C5B9-4C85-AD16-D6CBAC326631Q37669043-9877C86C-1C19-48AD-B44C-642A35F9F795Q37730595-777CB4A1-9B35-4B1A-A6DE-1B7691582474Q37736060-9A09DCFB-E4A7-4755-8110-CC01B34EF06BQ38617383-2AE39580-48AE-4E55-84E8-D13245A0D40CQ38653463-FE4231E7-42E7-4743-94BC-CCD9A3F00230Q38813162-A1995CF0-2C1D-44FD-9539-1C3661664D2EQ39005867-E982D677-E886-4FBC-8D24-BB3E7CF6D698Q39213490-3A602F1C-70D8-44FA-8016-F45A98D96580Q39266110-4CE869F3-092C-4530-B533-E6D9EB675F21Q41386264-67724910-CC33-417D-8EBE-3952BC8B9F33Q47296270-9F013722-C72F-4795-9C0F-6677043C1C44Q47664267-4073671F-B229-4D82-9ECE-FC277FA14EA7Q47741649-7D8E2BF6-5657-4EA4-B1EB-DA0EC660DB98Q47744428-9503CEEB-DED7-41C0-972C-69A47AD768BAQ47856901-3ED3AEEF-B707-433D-8FE9-FEAFDE98A99FQ48152599-2BFCC389-3CFD-41F6-A626-E495F7C75C9FQ48251989-04DCB5F7-E8C3-4A74-A565-7EE5E4458D13Q48302132-F4A7EA6C-009B-4BCC-B05B-3B440A9EE4C9Q49456987-14B4F214-5755-410C-A9D8-48D815EF45F7Q49993935-0B9D15C7-9FC3-46D4-85B1-CD4A632F033CQ50601534-FEBFB598-A289-43D5-81A0-87DE61E15810Q51738023-E12A9CDD-CB28-49AD-9D1F-0ED917275251Q53083035-179A7DA9-0BE1-498C-92BE-E5F84D69EDC7Q54127832-2E1BF88C-2537-4B64-9AA5-BA98DDF9830FQ55049877-35DF56FC-C235-4E17-991F-783E243AD6D6Q55360987-6D64A787-A928-43AA-91AC-C670BF3914F3Q55381801-893D0A3A-AE77-41FA-88E1-560E01DFB322Q55666180-115B0025-96FD-4F23-9809-A06907898432Q57483443-AA20A3C4-FAD2-4509-9B96-3F003BA9530CQ57483947-178FF9A4-48FF-455D-B797-BE289F021D0CQ58585573-E3CE1755-58C4-4C7D-B9F8-102F9497FF53Q58618185-CE071449-14A8-4891-8F27-EB845981B86B
P2860
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
@en
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
@nl
type
label
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
@en
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
@nl
prefLabel
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
@en
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
@nl
P2093
P2860
P356
P1476
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
@en
P2093
Charles L Loprinzi
David Biggs
Heshan Liu
Jacqueline M Lafky
Kathryn J Ruddy
Leah Dietrich
Madhuri Bajaj
Rudolph M Navari
Steven F Powell
P2860
P304
P356
10.1056/NEJMOA1515725
P407
P577
2016-07-01T00:00:00Z